Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency.

[1]  H. Farkas.  Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets , 2019, Expert opinion on therapeutic targets.

[2]  M. Cicardi,et al.  Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema , 2018, Expert review of clinical immunology.

[3]  M. Riedl,et al.  Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema , 2018, Clinical Reviews in Allergy & Immunology.

[4]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[5]  M. Cicardi,et al.  Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. , 2017, Allergy and asthma proceedings.

[6]  William H. Yang,et al.  Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial , 2017, The Lancet.

[7]  H. Farkas,et al.  A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum. , 2017, Immunology letters.

[8]  A. Kaplan,et al.  Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. , 2017, Immunology and allergy clinics of North America.

[9]  J. Bernstein,et al.  Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.

[10]  H. Farkas,et al.  Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  H. Farkas,et al.  Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. , 2014, Allergy and asthma proceedings.

[12]  H. Farkas,et al.  The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency , 2014, Orphanet Journal of Rare Diseases.

[13]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  H. Longhurst,et al.  Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema , 2014, EJD. European journal of dermatology.

[15]  T. Craig,et al.  Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys. , 2013, Allergy and asthma proceedings.

[16]  R. Lockey,et al.  Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  K. Obtulowicz,et al.  Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study , 2013, Allergy.

[18]  H. Farkas,et al.  Short‐term prophylaxis in hereditary angioedema due to deficiency of the C1‐inhibitor – a long‐term survey , 2012, Allergy.

[19]  W. Lumry,et al.  Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. , 2012, Allergy and asthma proceedings.

[20]  M. Triggiani,et al.  Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  Tom Bowen,et al.  International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.

[22]  K. Bork,et al.  Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[23]  S. Broesby‐Olsen,et al.  Rapid resolution of erythema marginatum after icatibant in acquired angioedema. , 2011, Acta dermato-venereologica.

[24]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[25]  H. Farkas,et al.  Disease expression in women with hereditary angioedema. , 2008, American journal of obstetrics and gynecology.

[26]  H. Farkas,et al.  Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema , 2007 .